复方消化酶联合雷贝拉唑及多潘立酮治疗功能性消化不良效果探讨  

Effect of Compound Digestive Enzyme Combined with Rabeprazole and Domperidone in the Treatment of Functional Dyspepsia

作　　者：毛虹[1] MAO Hong(Department of Gastroenterology,the First People's Hospital of Taicang City,Taicang,Jiangsu Province,215400 China)

机构地区：[1]江苏省太仓市第一人民医院消化内科

出　　处：《世界复合医学》2019年第12期180-182,共3页World Journal of Complex Medicine

摘　　要：目的探讨针对功能性消化不良(FD),采取复方消化酶+雷贝拉唑+多潘立酮联合治疗方法治疗疾病的效果。方法将该院2018年1月-2019年2月收治的82例FD患者随机分成研究组(n=41)与对照组(n=41),对照组采取雷贝拉唑联合多潘立酮的治疗方法,而研究组治疗上,主要是在对照组的用药基础上加用复方消化酶治疗,观察组两组患者治疗效果及安全性。结果对症治疗后,研究组在早饱、上腹烧灼感、餐后饱胀感、上腹疼痛等症状分别为(0.84±0.12)分、(0.77±0.14)分、(0.82±0.15)分、(0.88±0.16)分,对照组分别为(1.26±0.17)分、(1.16±0.16)分、(1.29±0.17)分、(1.33±0.27)分,研究组治疗后评分明显低于对照组,差异有统计学意义(t=12.924、11.746、13.274、9.181,P=0.000、0.000、0.000、0.000);治疗后,研究组组胃泌素-17(G-17)水平分别为(11.28±1.28)μmol/L,血浆胃动素(MTL)为(152.26±14.45)μg/mL,对照组分别为(8.45±1.02)μmol/L、(115.56±11.84)μg/mL,研究组指标显著高于对照组,组间差异有统计学意义(t=11.072、12.579,P=0.000、0.000);治疗期间研究组不良反应发生率为4.88%,对照组7.32%,两组患者不良反应发生率上差异无统计学意义(χ^2=0.231,P=0.644>0.05)。结论临床中在治疗FD上,采取复方消化酶联合雷贝拉唑与多潘立酮的治疗方法,可取得显著的治疗效果,且治疗期间患者不良反应发生率也较低,值得推广。Objective To investigate the effect of combined digestive enzyme + rabeprazole + domperidone in the treatment of disease for functional dyspepsia(FD). Methods 82 patients with FD who were admitted to our hospital from January 2018 to February 2019 were randomLy divided into study group(n=41) and control group(n=41). The control group received rabeprazole combined with domperidone. The treatment group was treated with compound digestive enzymes on the basis of the control group, and the treatment effect and safety of the two groups were observed. Results After symptomatic treatment, the symptoms of early satiety, upper abdomen burning, postprandial fullness, and upper abdominal pain were(0.84 ±0.12)points,(0.77 ±0.14)points, and(0.82 ±0.15)points,(0.88 ±0.16)points, the control group were(1.26±0.17)points,(1.16±0.16)points,(1.29±0.17)points,(1.33±0.27)points, and the study group scored significantly lower than the control group. The difference was statistically significant(t =12.924, 11.746, 13.274, 9.181, P =0.000,0.000, 0.000, 0.000);after treatment, the level of gastrin-17(G-17) in the study group was(11.28 ±1.28) μmol/L, plasma motilin(MTL) was(152.26±14.45) μg/mL, and the control group was(8.45±1.02) μmol/L,(115.56±11.84) μg/mL, the study group was significantly higher than the control group, the difference between the groups was statistically significant( t =11.072, 12.579, P =0.000,0.000);the incidence of adverse reactions in the study group was 4.88% during the treatment period, and 7.32% in the control group,the difference in the incidence of adverse reactions between the two groups. the difference was not statistically significant( χ^2=0.231,P=0.644 >0.05). Conclusion In the treatment of FD, the combination of compound digestive enzymes combined with rabeprazole and domperidone can achieve significant therapeutic effects, and the incidence of adverse reactions during treatment is also low, which is worth promoting.

关 键 词：复方消化酶 雷贝拉唑 多潘立酮 功能性消化不良 疗效 

分 类 号：R573[医药卫生—消化系统]